StreetAlpha.app
Home › Stocks › ELVN

Enliven Therapeutics, Inc. (ELVN)

Healthcare
$46.85
▼ −1.62%
LAST CLOSE · NOV 17

Enliven Therapeutics develops small molecule drugs, led by an investigational kinase inhibitor for chronic myeloid leukemia. It last closed at $46.85 on Nov 17, down 1.62% on the day. The average 12-month price target from 3 analysts is $72.67 (+55.1% from the last close), with a high of $75.00 and a low of $70.00. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell). In the past 30 days there were 1 dark pool print totaling $897K, the largest $897K.

AI Auto Pilots
Is ELVN in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$113.5M
EPS (diluted)
−$1.69
Free cash flow
−$66.4M
Valuation
Market cap
$3.4B
73.6M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$151.7M
At Sep 30
Shareholder equity
$876.9M
Shares outstanding
73.6M
At Oct 28
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$51.4M−$51.4MFY2021FY2022: −$37.7M−$37.7MFY2022FY2023: −$71.6M−$71.6MFY2023FY2024: −$89.0M−$89.0MFY2024FY2025: −$103.7M−$103.7MFY2025

From ELVN's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Last report
Nov 5
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 3 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
3firms
3 Buy0 Hold0 Sell
Each firm's latest rating on ELVN in the past 90 days
Average 12-month target
$72.67
▲ 55.1% upside

Based on 3 analysts who set a price target on ELVN in the past 90 days. The average target is $72.67, with a high of $75.00 and a low of $70.00, compared with the last close of $46.85.

Low $70.00Avg $72.67High $75.00
Blue marker: last close $46.85
Highest target$75.00
Average target$72.67
Lowest target$70.00
Latest rating changes
HC Wainwright & Co.Target raised
Oct 19Buy$64 → $73
Morgan StanleyInitiated
Oct 2Buy$70
JP MorganInitiated
Oct 1Buy$75
BarclaysInitiated
Aug 18Buy$78
MizuhoTarget raised
Aug 18Buy$62 → $73
DateFirmActionRatingPrice target
Oct 19HC Wainwright & Co.Target raisedBuy$64 → $73
Oct 2Morgan StanleyInitiatedBuy$70
Oct 1JP MorganInitiatedBuy$75
Aug 18BarclaysInitiatedBuy$78
Aug 18MizuhoTarget raisedBuy$62 → $73
Loading…

Technical Analysis

ELVN · as of the Nov 17 close · updated after every close
Uptrend

The stock is 2% above its 20 day and 2% above its 50 day average. It is 6% above its 200 day average, so the longer trend is still up. Momentum is improving (RSI 51). The nearest support is the 20 day average at $46.05, and the nearest resistance the Pivot at $46.88.

Short trendBullish
Long trendBullish
MomentumImproving
StretchNormal
VolatilityNormal, 4.6%/day
Key levels
$62.3252 week high+33.0%
$50.90100 day average+8.6%
$47.72Pivot R1+1.9%
$47.36Swing high (Jun 12)+1.1%
$46.88Pivot+0.1%
$46.85Last close
$46.0520 day average−1.7%
$46.02Pivot S1−1.8%
$45.9550 day average−1.9%
$44.18Swing low (Sep 25)−5.7%
$44.03200 day average−6.0%
$14.7952 week low−68.4%
Indicators
RSI (14)51.10Middle of its rangeNeutral
MACD1.09Above its signal lineBullish
Stochastic52.4Middle of its rangeNeutral
ADX (14)24.6Weak trend
Williams %R-59.7Oversold below −80, overbought above −20Neutral
CCI (20)24.2Oversold below −100, overbought above 100Neutral
Rate of change+4.5%Change over 10 sessionsBullish
ATR (14)$2.17Typical daily range, 4.6% of price
MA 10Below
MA 20Above
MA 50Above
MA 100Below
MA 200Above
What happened before, for ELVN

What happened before

See how ELVN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow ELVN usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How ELVN has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in ELVN in the last 90 days.

Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
1
Notional
$897K
Largest print
$897K
Loading…

ELVN Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲135 buying vs 85 selling
  • ▲Held by funds +2.9 pts
  • ▲Funds holding +5
  • ▲Superinvestors: 2 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding218213+2.3%
In funds' top 101013−23.1%
Held by funds112.3%109.3%+2.9 pts
New / increased38 / 9761 / 86−8.2%
Reduced / sold out53 / 3248 / 20+25.0%
Put/call ratio0.010.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ELVN institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ELVN is in one of them and how their past ELVN trades turned out.

ELVN in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ELVN in an article yet. Here's the latest on the wider market.

About Enliven Therapeutics

Enliven Therapeutics is a biopharmaceutical company based in Burlingame, California, that develops small molecule drugs. Its lead candidate, ELVN-001, is a kinase inhibitor being studied for chronic myeloid leukemia, a blood cancer, in patients whose disease has become resistant or intolerant to existing treatments. The company also runs research programs on other targeted therapies aimed at unmet medical needs.

Headquarters
Burlingame, CA